This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Nevro (NVRO) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
by Zacks Equity Research
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.
Here's Why You Should Retain Nevro (NVRO) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Hologic (HOLX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP
by Zacks Equity Research
Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.
Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage
by Zacks Equity Research
Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.
Nevro (NVRO) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Nevro (NVRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass
by Zacks Equity Research
Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -1.16% and 2.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nevro (NVRO) Up 8.6% Since Last Earnings Report?
by Zacks Equity Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro (NVRO) Q2 Earnings Surpass Estimates, Revenues Lag
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues rise on a year-over-year basis in Q2 despite pandemic-led business challenges.
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 12.68% and -2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.